Take­da’s post-merg­er deals con­tin­ue as OTC sub­sidiary is pre­pared for sale

Take­da has been bur­dened un­der moun­tains of debt since ac­quir­ing Shire for $62 bil­lion 18 months ago, but one of the com­pa­ny’s biggest moves yet to re­lieve the stress could be on the hori­zon.

The Japan­ese phar­ma is prepar­ing a bid­ding war for its $3.7 bil­lion over-the-counter sub­sidiary, a sale that would dwarf pre­vi­ous spin­offs. Any trans­ac­tion would be the lat­est in what’s been a long string of sell-offs, as Take­da march­es un­flinch­ing­ly to­ward its ul­ti­mate goal of shed­ding $10 bil­lion in as­sets.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.